For Cytogenetic-Test Providers, the Devil's in the Interpretation of Array Results | GenomeWeb

By Justin Petrone

Laboratories that offer array-based tests for genetic abnormalities are generally satisfied with the quality of the technology platforms available, but are sometimes challenged by the interpretation of the ambiguous data that arrays can provide.

Because of this, companies targeting the clinical cytogenetics market are investing more resources in developing software tools to support their clients as they seek to determine whether variation picked up by arrays is benign or pathogenic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.